Tham khảo Ethinylestradiol sulfonate

  1. 1 2 3 4 5 6 7 8 9 10 11 12 13 Schwarz S, Onken D, Schubert A (tháng 7 năm 1999). “The steroid story of Jenapharm: from the late 1940s to the early 1970s”. Steroids. 64 (7): 439–45. doi:10.1016/S0039-128X(99)00003-3. PMID 10443899. 6.2. New estrogens. In 1967, Jenapharm, in conjunction with the Academy of Sciences (Kurt Ponsold, Gu¨nter Bruns, and Kurt Schubert in Jena and Hans Schick and Bernard Lu¨cke in Berlin), started a program of searching for new estrogens. [...] orally administered, strongly active estrogens with a depot effect. [...] the second objective was successfully attained. The rationale that an a-branched alkanesulfonic acid ester of ethinyl estradiol with a medium chain length should lead to a depot effect without the danger of active ingredient accumulation on longer usage [15] led in 1978 to the first once-a-week oral contraceptive (DEPOSISTONt), a combination of ethinylestradiol 3-isopropylsulfonate (17) and norethisterone acetate [16]. TURISTERONt, an estrogenic monotherapy with compound 17 that can still justify its position today [17], followed in 1980, as a therapy of prostate cancer. [...]
  2. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 Michael Oettel; Ekkehard Schillinger (6 tháng 12 năm 2012). Estrogens and Antiestrogens II: Pharmacology and Clinical Application of Estrogens and Antiestrogen. Springer Science & Business Media. tr. 248, 277, 369, 540, 542. doi:10.1007/978-3-642-60107-1. ISBN 978-3-642-60107-1.
  3. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 Elger W, Palme HJ, Schwarz S (tháng 4 năm 1998). “Novel oestrogen sulfamates: a new approach to oral hormone therapy”. Expert Opin Investig Drugs. 7 (4): 575–89. doi:10.1517/13543784.7.4.575. PMID 15991994.
  4. 1 2 3 4 5 6 7 Gürtler R, Tanneberger S, Bodek B, Morack G (1982). “[Clinical experience with the depot estrogen Turisteron in the treatment of metastatic breast cancer (author's transl)]”. Arch. Geschwulstforsch. (bằng tiếng Đức). 52 (2): 129–39. PMID 7103689.Quản lý CS1: ngôn ngữ không rõ (liên kết)
  5. 1 2 3 4 5 6 7 8 Höfling, G.; Heynemann, H. (1998). “Die orale Östrogentherapie des fortgeschrittenen Prostatakarzinoms — Anlaß für eine Neubewertung?” [Oral Estrogen Therapy for Advanced Prostate Cancer — Reason for Revaluation?]. Der Urologe B. 38 (2): 165–170. doi:10.1007/s001310050185. ISSN 0042-1111.
  6. 1 2 3 Dörner G, Schnorr D, Stahl F, Rohde W (tháng 12 năm 1985). “Successful treatment of prostatic cancer with the orally active depot estrogen ethinylestradiol sulfonate (Turisteron)”. Exp. Clin. Endocrinol. 86 (2): 190–6. doi:10.1055/s-0029-1210486. PMID 3912197.
  7. 1 2 S. Monfardini; K. Brunner; D. Crowther; S. Eckhardt; D. Olive; S. Tanneberger; A. Veronesi; J.M.A. Whitehouse; R. Wittes (1987). Manual of Adult and Paediatric Medical Oncology. Springer Science & Business Media. tr. 196–. doi:10.1007/978-3-642-82489-0. ISBN 978-3-642-82489-0.
  8. 1 2 3 4 5 6 7 Index Nominum 2000: International Drug Directory. Taylor & Francis. tháng 1 năm 2000. tr. 412–. ISBN 978-3-88763-075-1.
  9. 1 2 Sweetman, Sean C. biên tập (2009). “Sex hormones and their modulators”. Martindale: The Complete Drug Reference (ấn bản 36). London: Pharmaceutical Press. tr. 2102. ISBN 978-0-85369-840-1.
  10. 1 2 https://www.drugs.com/international/turisteron.html
  11. 1 2 Stahl F, Schnorr D, Bär CM, Fröhlich G, Dörner G (1989). “Suppression of plasma androgen levels with a combination therapy of depot-estrogen (Turisteron) and Dexamethasone in patients with prostatic cancer”. Exp. Clin. Endocrinol. 94 (3): 239–43. doi:10.1055/s-0029-1210905. PMID 2630306.
  12. 1 2 Göretzlehner G, Köhler G (1990). “Charakteristik der Estrogene und Gestagene” [Characteristics of estrogens and gestagens]. Z Arztl Fortbild (Jena) (bằng tiếng Đức). 84 (1–2): 7–12. ISSN 0012-0219. PMID 2184606.Quản lý CS1: ngôn ngữ không rõ (liên kết)
  13. 1 2 Wolfgang Hinkelbein; Kurt Miller; Thomas Wiegel (7 tháng 3 năm 2013). Prostatakarzinom — urologische und strahlentherapeutische Aspekte: urologische und strahlentherapeutische Aspekte [Prostate carcinoma — urological and radiotherapeutic aspects: urological and radiotherapeutic aspects]. Springer-Verlag. tr. 92–93, 99. ISBN 978-3-642-60064-7.
  14. 1 2 3 4 5 J. Elks (14 tháng 11 năm 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. tr. 523–. ISBN 978-1-4757-2085-3.
  15. 1 2 3 Guddat HM, Schnorr D, Dörner G, Stahl F, Rohde W (tháng 12 năm 1987). “[Behavior of LH, FSH, total testosterone, free testosterone and SHBG serum levels in the therapy of prostatic cancer with Turisteron (ethinyl estradiol sulfonate)]”. Z Urol Nephrol (bằng tiếng Đức). 80 (12): 665–8. PMID 3126615.Quản lý CS1: ngôn ngữ không rõ (liên kết)
  16. ↑ IARC Working Group on the Evaluation of Carcinogenic Risks to Humans; World Health Organization; International Agency for Research on Cancer (2007). Combined Estrogen-progestogen Contraceptives and Combined Estrogen-progestogen Menopausal Therapy. World Health Organization. tr. 157–. ISBN 978-92-832-1291-1.
  17. ↑ Stephen J. Winters; Ilpo T. Huhtaniemi (25 tháng 4 năm 2017). Male Hypogonadism: Basic, Clinical and Therapeutic Principles. Humana Press. tr. 307–. ISBN 978-3-319-53298-1.
  18. ↑ Schnorr D, Dörner G, Stahl F, Rohde W, Guddat HM (1987). “[Conservative therapy of prostate cancer using Turisteron]”. Z Urol Nephrol (bằng tiếng Đức). 80 (3): 149–57. PMID 3111122.Quản lý CS1: ngôn ngữ không rõ (liên kết)
  19. ↑ Benno Runnebaum; Thomas Rabe (17 tháng 4 năm 2013). Gynäkologische Endokrinologie und Fortpflanzungsmedizin: Band 1: Gynäkologische Endokrinologie. Springer-Verlag. tr. 88–. ISBN 978-3-662-07635-4.
  20. ↑ Elger W, Barth A, Hedden A, Reddersen G, Ritter P, Schneider B, Züchner J, Krahl E, Müller K, Oettel M, Schwarz S (2001). “Estrogen sulfamates: a new approach to oral estrogen therapy”. Reprod. Fertil. Dev. 13 (4): 297–305. doi:10.1071/RD01029. PMID 11800168.
  21. ↑ Elger W, Wyrwa R, Ahmed G, Meece F, Nair HB, Santhamma B, Killeen Z, Schneider B, Meister R, Schubert H, Nickisch K (tháng 1 năm 2017). “Estradiol prodrugs (EP) for efficient oral estrogen treatment and abolished effects on estrogen modulated liver functions”. J. Steroid Biochem. Mol. Biol. 165 (Pt B): 305–311. doi:10.1016/j.jsbmb.2016.07.008. PMID 27449818.